Group 1 - The core point of the article is that the hearing for the winding-up petition of Greentown China Holdings has been further postponed to November 3, 2025 [1] Group 2 - The High Court issued an order to delay the hearing of the winding-up petition originally scheduled for August 4, 2025 [1] - This delay indicates ongoing legal proceedings related to the company's financial situation [1] - The postponement may impact investor sentiment and the company's operational strategies moving forward [1]

绿景中国地产(00095)发布公告，于2025年8月4日的高等法院聆讯中，高等法院颁令将呈请聆讯进一步 延期至2025年11月3日。 ...

格隆汇8月4日丨绿景中国地产(00095.HK)公布，于2025年8月4日的高等法院聆讯中，高等法院颁令将呈 请聆讯进一步延期至2025年11月3日。 ...

Group 1 - The core point of the article is that Greentown China Holdings (00095) announced a court hearing scheduled for August 4, 2025, has been postponed to November 3, 2025 [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責， 對其準確性或完整性亦不發表任何聲明，並明確表示，概不就因本公告全部或任何 部份內容而產生或因依賴該等內容而引致之任何損失承擔任何責任。 （於開曼群島註冊成立的有限公司） （ 香港聯交所股份代號：95） 有關清盤呈請的信息更新 承董事會命 綠景（中國）地產投資有限公司 主席 黃敬舒 香港，二零二五年八月四日 於本公告日期，本公司執行董事為黃敬舒女士（主席兼行政總裁）、葉興安先生、 黃浩源先生及李俞霏小姐；及獨立非執行董事陳觀發先生、焦捷女士及王廷丹女士。 茲提述綠景（中國）地產投資有限公司（「本公司」）日期為二零二五年 二月五日，二零二五年四月九日，二零二五年五月十四日及二零二五年七月 九日之公告（「該等公告」）。除非另有所指，本公告所用詞彙與該等公告 中所界定該等詞彙的涵義相同。 於二零二五年八月四日的高等法院聆訊中，高等法院頒令將呈請聆訊進一步 延期至二零二五年十一月三日。 本公司將就有關呈請的任何重大發展知會其股東及投資者，並適時另行刊發 公告。 本公司股東及其他投資者於買賣本公司證券時務請審慎行事及如對自己的處 境和應採取的行動有 ...

智通财经8月4日电，绿景中国地产的清盘聆讯押后至11月3日。 ...

截至月份: 2025年7月31日 狀態: 新提交 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 致：香港交易及結算所有限公司 公司名稱: 綠景(中國)地產投資有限公司 呈交日期: 2025年8月1日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 00095 | 說明 | 普通股 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 30,000,000,000 | HKD | | 0.01 | HKD | | 300,000,000 | | 增加 / 減少 (-) | | | | | | | HKD | | | | 本月底結存 | | | 30,000,000,000 | HKD | | 0.01 | HKD | | 300,000,000 ...

Group 1 - The core point of the news is that Hehua Co., Ltd. is planning a potential share transfer that may lead to a change in its controlling shareholder and actual controller, as notified by its major shareholder, Ningbo Yinyi Holdings Co., Ltd. [1] - The company has announced a temporary suspension of its stock trading starting from July 31, due to the uncertainty surrounding the share transfer, with an expected suspension period of no more than two trading days [3] - Hehua Co., Ltd. is also participating in the establishment of a venture capital fund with a total initial subscription of 11 million yuan, where the company will contribute 5 million yuan, accounting for 45.45% of the total [4] Group 2 - Hehua Co., Ltd. primarily engages in the research, production, and sales of pharmaceutical intermediates, as well as the commissioned processing and sales of urea [5] - On July 30, the company's stock price experienced a significant increase, reaching a closing price of 8.02 yuan per share, with a total market capitalization of 2.9 billion yuan [5][6]

Core Viewpoint - Hehua Co., Ltd. (河化股份) announced a suspension of its stock trading due to a planned change in control, with the suspension expected to last no more than two trading days [2][4]. Group 1: Company Background - Hehua Co., Ltd. primarily engages in the research, production, and sales of pharmaceutical intermediates, as well as the commissioned processing and sales of urea [5]. - The company’s subsidiary, Nansong Pharmaceutical, specializes in the development and production of pharmaceutical intermediates, with products sold domestically and internationally, including to countries like India and Finland [5]. - Hehua Co., Ltd. has undergone two changes in actual control since its establishment in 1993, with the current controlling shareholder being Ningbo Yinyi Holdings Co., Ltd. (银亿控股) since 2016 [5]. Group 2: Recent Developments - Ningbo Yinyi Holdings is currently planning a share transfer that may lead to a change in the controlling shareholder and actual controller of Hehua Co., Ltd. [4]. - The company reported a revenue of 40.83 million yuan in Q1, a year-on-year decrease of 34.05%, but achieved a net profit of 1.36 million yuan, marking a turnaround from losses [5]. - Hehua Co., Ltd. has faced operational challenges, including a significant decline in performance after the acquisition of Nansong Pharmaceutical, which was intended to pivot the business towards fine chemical production [8]. Group 3: Financial and Market Performance - Hehua Co., Ltd. has seen its stock price increase by over 40% this year, with a notable surge on July 30, when the stock hit the daily limit [9]. - The company is focusing on enhancing its core business and expanding market reach to identify new profit growth points [9].

Group 1 - The core point of the news is that Hehua Co., Ltd. (河化股份) is undergoing a potential change in its controlling shareholder and actual controller due to a planned equity transfer by its major shareholder, Ningbo Yinyi Holdings Co., Ltd. [1] - The company has announced a stock suspension starting from July 31, 2023, to ensure fair information disclosure and protect investor interests, with the suspension expected to last no more than two trading days [3] - Hehua Co., Ltd. has recently signed an agreement to invest 5 million yuan in a venture capital fund, aiming to optimize the efficiency of its capital usage and leverage professional resources to seize market opportunities [4] Group 2 - The total initial capital commitment for the venture capital fund is 11 million yuan, with Hehua Co., Ltd. contributing 5 million yuan, representing 45.45% of the total [4] - The fund will primarily invest in high-quality equity targets in the fields of raw material pharmaceutical enterprises and synthetic biomedicine, with an investment period of three years and an exit period of two years [4] - As of July 30, 2023, Hehua Co., Ltd.'s stock price experienced a significant increase, closing at 8.02 yuan per share, with a total market capitalization of 2.9 billion yuan [4]